The risk of posterior reversible encephalopathy syndrome (pres) with tyrosine kinase inhibitors: A disproportionality analysis from VigiBase and AERS databases

被引：0
|
作者：
Velez-Nandayapa, Luis [1 ]
Das, Anusmita [2 ]
Saxena, Amit [2 ]
Parulekar, Vishaka [3 ]
Chhabra, Naveen [3 ]
Izquierdo, Miguel [4 ]
De Zeeuw, Pierre [5 ]
Schaart, Edwin [6 ]
Eisinger, Johannes [5 ]
机构：
[1] Univ Basel, Basel, Switzerland
[2] Novartis, Safety Signal Detect MQM, Basel, Switzerland
[3] Novartis, Patient Safety Oncol, Hyderabad, India
[4] Novartis, Clin Dev Oncol, Basel, Switzerland
[5] Novartis, Patient Safety Oncol, Basel, Switzerland
[6] Novartis, Basel, Switzerland
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
924
引用
收藏
页码：425 / 426
页数：2
相关论文
共 49 条
  • [41] Single institution experience of posterior reversible encephalopathy syndrome (PRES) associated with high risk pediatric ALL induction therapy: Is there a role of pharmaco-ethnicity
    Mittal, Nupur
    Nagarajan, Murali
    Heydemann, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database
    Khouri, Charles
    Hlavaty, Alex
    Roustit, Matthieu
    Cracowski, Jean-Luc
    Chaumais, Marie-Camille
    Humbert, Marc
    Montani, David
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (06)
  • [43] CARDIOVASCULAR SIDE EFFECTS OF TYROSINE KINASE INHIBITORS USED FOR CANCER THERAPY: ANALYSIS OF SAFETY REPORTS FROM THE WORLD HEALTH ORGANIZATION VIGIBASE DATASETS
    Sunder, Sunitha Shyam
    Karthikeyan, Badri
    Pokharel, Saraswati
    Fernandez, Stanley F.
    Sharma, Umesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1922 - 1922
  • [44] Analysis of Risk Factors Associated With Poor Outcome in Posterior Reversible Encephalopathy Syndrome After Treatment in Children: Systematic Review and Meta-Analysis
    Hun, Marady
    Tian, Jidong
    Xie, Min
    She, Zhou
    Abdirahman, Amin Sheikh
    Han, Phanna
    Wan, Wuqing
    Wen, Chuan
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [45] Risk of Myopathy Associated With DPP-4 Inhibitors in Combination With Statins: A Disproportionality Analysis Using Data From the WHO and French Spontaneous Reporting Databases
    Labat, Vanessa
    Arnaud, Mickael
    Miremont-Salame, Ghada
    Salvo, Francesco
    Begaud, Bernard
    Pariente, Antoine
    DIABETES CARE, 2017, 40 (03) : E27 - E29
  • [46] Clinico-radiological Profile of Posterior Reversible Encephalopathy Syndrome and Its Associated Risk Factors in PICU: A Single-center Experience from a Tertiary Care Hospital in Bhubaneswar, Odisha
    Behera, Chinmay K.
    Jain, Mukesh K.
    Mishra, Reshmi
    Jena, Pratap K.
    Dash, Santosh K.
    Sahoo, Ranjan K.
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2020, 24 (12) : 1223 - 1229
  • [47] RISK OF TREATMENT-RELATED TOXICITIES FROM EGFR TYROSINE KINASE INHIBITORS: A META-ANALYSIS OF CLINICAL TRIALS OF GEFITINIB, ERLOTINIB AND AFATINIB IN ADVANCED EGFR MUTATED NONSMALL CELL LUNG CANCER
    Ding, P. N.
    Lord, S. J.
    Bray, V.
    Gebski, V.
    Lee, C. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 41 - 41
  • [48] Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer
    Li, Zhifei
    Chu, Hongyuan
    Huang, Sicheng
    Li, Runze
    Qiu, Bin
    Tan, Fengwei
    Xue, Qi
    Gao, Shugeng
    He, Jie
    JOURNAL OF THORACIC DISEASE, 2024, 16 (10)
  • [49] Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Ding, Pei Ni
    Lord, Sarah J.
    Gebski, Val
    Links, Matthew
    Bray, Victoria
    Gralla, Richard J.
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (04) : 633 - 643
12345